Amgen places a $415 million bet that human genetics will boost drug discovery.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
In an experimental trial, surgeons have implanted deep-brain stimulators into U.S. and Canadian Alzheimer’s patients.
Regulatory approval of a gene therapy treatment in Europe could spark broader patient access to the technology.
DNA sequencing is the most cost-effective way to screen for drug-resistant strains in prisons, say Stanford researchers.
Researchers are using genomics to breed a better Thanksgiving bird.
Cell-free fetal DNA test can be primary screen for aneuoploidy-risk pregnancies, says Ob-Gyn society
A startup called GenePeeks will identify recessive diseases that could show up in children of sperm-bank clients and donors.
The sleek device tallies simple movements like running and biking.
The system automatically pulls up patient files and lets nurses use mobile devices to document work.
The organ-mimicking microdevice may one day reduce the need for animal testing.